Vutrisiran
Full Prescribing Information for AMVUTTRA® (vutrisiran)
Explore a range of clinical and educational resources related to the use of vutrisiran in patients with the polyneuropathy of ATTRv (also known as hATTR) amyloidosis.
If you require any further information on vutrisiran, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.
More Information
For more information about data regarding vutrisiran, please visit our Congresses and Publications resources page.
ATTR-CM HELIOS-B Data Summary
ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.
Slide Deck
HELIOS-B Plain Language Summary
This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)
Plain Language Summary
HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
Slide Deck
Insights from the HELIOS-A Study
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
Slide Deck
